- AU$14.64m
- AU$15.95m
- AU$14.61m
Brief: Impedimed Ltd Says Half Year Revenue Of A$4.8 Million
Brief: Impedimed Ltd Says HY Net Loss Attributable A$9.7 Million
Brief: ImpediMed Announces Appointment Of Independent Non-Executive Chair
Brief: Impedimed Posts Unaudited Revenue Of A$2.3 Million For Quarter
Australia's ImpediMed drops most in 7 months after CEO, CFO resign
Brief: ImpediMed Ltd SaysRick Valencia Will Step Down From His Role As Managing Director And CEO
Brief: Impedimed Ltd Says Q1 Total Revenue A$2.5 Million, Down 12% YoY
Brief: Impedimed Posts FY Net Loss Attributable A$20.5 Million
Brief: Impedimed Executing Towards Profitability In Oncology
Brief: Impedimed Says Board Recommending Shareholders Vote Against All 8 Proposed Resolutions
Australia's ImpediMed gains on Canaccord's PT raise
Brief: Impedimed Receives Firm Commitments To Raise A$20 Million (Before Costs)
Australia's ImpediMed falls to 1-month low on discounted placement
Brief: Impedimed Seeks Trading Halt Pending Announcement On Outcome Of Proposed Capital Raising
Brief: ImpediMed Announces Clearance Of SOZO Pro By U.S. Food & Drug Administration
Brief: ImpediMed Says Qtrly A$2.7M Total Revenue, Flat YoY
Brokerage Canaccord says NCCN guidelines are a positive milestone for Australia's ImpediMed
Brief: Impedimed Posts HY Net Loss Of A$10.8 Mln Versus Loss A$8.9 Mln
Brief: ImpediMed Ltd Says Qtrly Total Revenue A$2.8 Mln